147 related articles for article (PubMed ID: 25310020)
21. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
PLoS One; 2011 Feb; 6(2):e17578. PubMed ID: 21386910
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract][Full Text] [Related]
23. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
24. Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis.
Chen X; Liu X; Deng B; Martinka M; Zhou Y; Lan X; Cheng Y
Sci Rep; 2018 Nov; 8(1):16867. PubMed ID: 30442923
[TBL] [Abstract][Full Text] [Related]
25. Stage-specific prognostic biomarkers in melanoma.
Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
[TBL] [Abstract][Full Text] [Related]
26. Nuclear ING2 expression is reduced in human cutaneous melanomas.
Lu F; Dai DL; Martinka M; Ho V; Li G
Br J Cancer; 2006 Jul; 95(1):80-6. PubMed ID: 16755297
[TBL] [Abstract][Full Text] [Related]
27. Loss of SNF5 expression correlates with poor patient survival in melanoma.
Lin H; Wong RP; Martinka M; Li G
Clin Cancer Res; 2009 Oct; 15(20):6404-11. PubMed ID: 19808872
[TBL] [Abstract][Full Text] [Related]
28. Melastatin expression and prognosis in cutaneous malignant melanoma.
Duncan LM; Deeds J; Cronin FE; Donovan M; Sober AJ; Kauffman M; McCarthy JJ
J Clin Oncol; 2001 Jan; 19(2):568-76. PubMed ID: 11208852
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
30. The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas.
Cheng Y; Li J; Martinka M; Li G
Oncol Rep; 2010 Apr; 23(4):973-9. PubMed ID: 20204281
[TBL] [Abstract][Full Text] [Related]
31. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
32. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
33. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival.
Dai DL; Makretsov N; Campos EI; Huang C; Zhou Y; Huntsman D; Martinka M; Li G
Clin Cancer Res; 2003 Oct; 9(12):4409-14. PubMed ID: 14555513
[TBL] [Abstract][Full Text] [Related]
35. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
36. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.
Garrido-Ruiz MC; Rodriguez-Pinilla SM; Pérez-Gómez B; Rodriguez-Peralto JL
J Cutan Pathol; 2010 May; 37(5):542-8. PubMed ID: 19638168
[TBL] [Abstract][Full Text] [Related]
37. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma.
Lu J; Tang Y; Farshidpour M; Cheng Y; Zhang G; Jafarnejad SM; Yip A; Martinka M; Dong Z; Zhou J; Xu J; Li G
Carcinogenesis; 2013 Dec; 34(12):2778-88. PubMed ID: 24064223
[TBL] [Abstract][Full Text] [Related]
38. Nucleolin protein expression in cutaneous melanocytic lesions.
Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
[TBL] [Abstract][Full Text] [Related]
39. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
